Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 263 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR News digest – cancer blood test, gum disease and junk food... July 25, 2020 ESMO Calls for Cancer Care Integration in EU Global Health Resilience... March 24, 2026 Breakfast Ideas August 21, 2020 Woman Dances Through Chemo Sessions, Emphasizes Importances of Being ‘Joyful’ March 4, 2021 Load more HOT NEWS Man Gets His First Haircut In 15 Years To Join The... Reduction Not Only in Recurrences, but Also in Mortality, Observed for... FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a... Olive Oil Found to Reduce Risk of Death from Dementia, Cancer,...
